Structure posts early oral obesity data, delays larger readout

Product Description

Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks. | Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks.

Use of the Historial Weight Trajectory to Guide an Obesity Focused Patient Encounter - Endotext - NCBI Bookshelf

Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, and Cardiometabolic Disorders

Abstracts - 2023 - HIV Medicine - Wiley Online Library

Stachyose-Enriched α-Galacto-oligosaccharides Regulate Gut Microbiota and Relieve Constipation in Mice

Effects of microbiota-directed foods in gnotobiotic animals and undernourished children

Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies - ScienceDirect

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis: Molecular Therapy Methods & Clinical Development

Physiological roles of hydrogen sulfide in mammalian cells, tissues, and organs

09.29.23 Can Structure's obesity pill stack up to Big Pharma?; Scientists model preclinic after clinic - Questex